Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma

Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a potential therapeutic target, we systematically evaluated methods of ass...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2019-06, Vol.25 (11), p.3259-3265
Hauptverfasser:	Lassman, Andrew B, Roberts-Rapp, Lisa, Sokolova, Irina, Song, Minghao, Pestova, Ekaterina, Kular, Rupinder, Mullen, Carolyn, Zha, Zheng, Lu, Xin, Gomez, Erica, Bhathena, Anahita, Maag, David, Kumthekar, Priya, Gan, Hui K, Scott, Andrew M, Guseva, Maria, Holen, Kyle D, Ansell, Peter J, van den Bent, Martin J
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers, Tumor Clinical Trials, Phase I as Topic ErbB Receptors - genetics ErbB Receptors - metabolism Gene Amplification Gene Expression Profiling Genetic Testing Glioblastoma - diagnosis Glioblastoma - etiology Glioblastoma - metabolism Glioblastoma - therapy Humans Immunohistochemistry In Situ Hybridization, Fluorescence Precision Medicine - methods Precision Medicine - standards Real-Time Polymerase Chain Reaction Whole Exome Sequencing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!